Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1737-1743

  Fairey, Adrian S ^a   Daneshmand, Siamak ^a   Quinn, David ^a   Dorff, Tanya ^a   Dorin, Ryan ^a   Lieskovsky, Gary ^a   Schuckman, Anne ^a   Cai, Jie ^a   Miranda, Gus ^a   Skinner, Eila C ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Cisplatin; Cystectomy; Doxorubicin; Gemcitabine; Methotrexate; Neoadjuvant chemotherapy; Pathologic downstaging; Urinary bladder neoplasms; Vinblastine

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; PELVIS LYMPH NODE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA;

CISPLATIN; CYSTECTOMY; DOXORUBICIN; GEMCITABINE; METHOTREXATE; NEOADJUVANT CHEMOTHERAPY; PATHOLOGIC DOWNSTAGING; URINARY BLADDER NEOPLASMS; VINBLASTINE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CYSTECTOMY; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84886236988     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.07.005     Document Type: Article

References (20)

1. Siegal R., Ward E., Brawley O., et al. Cancer statistics, 2012. CA Cancer J Clin 2012, 2011:10-29.
2. Clinical practice guidelines in oncology: Bladder cancer ver. 2 National Comprehensive Cancer Network, Accessed August 2011. http://www.nccn.org.
3. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
4. Yafi F.A., Aprikian A.G., Chin J.L., et al. Contemporary outcomes of 2,287 patients with bladder cancer who were treated with radical cystectomy: A Canadian multicentre experience. BJU Int 2011, 108:539-545.
5. Advanced bladder cancer Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003, 361:1927-1934. Advanced Bladder Cancer Meta-analysis Collaboration.
6. Winquist E., Kirchner T.S., Segal R., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol 2004, 171:561-569.
7. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
8. Bellmunt J., Orsola A., Wiegel T., et al. Bladder cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2006, 17:450-456.
9. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
10. Kaneko G., Kikuchi E., Matsumoto K., et al. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. Jpn J Clin Oncol 2011, 41:908-914.
11. Dash A., Pettus J.A., Herr H.W., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience. Cancer 2008, 113:2471-2477.
12. Weight C.J., Garcia J.A., Hansel D.E., et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series. Cancer 2009, 115:792-799.
13. Scosyrev E., Messing E.M., van Wijngaarden E., et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012, 118:72-81.
14. Herchenhorn D., Dienstmann R., Peixoto F.A., et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol 2007, 33:630-638.
15. Dorin R.P., Daneshmand S., Eisenberg M.S., et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: A comparative mapping study. Eur Urol 2011, 60:946-952.
16. Stein J.P., Penson D.F., Cai J., et al. Radical cystectomy with extended lymphadenectomy: Evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol 2007, 177:876-882.
17. Urinary bladder. AJCC cancer staging manual 1997, American Joint Committee on Cancer, Lippincott-Raven, Philadelphia, PA. 5th edition. I.D. Fleming, J.S. Cooper, D.E. Henson (Eds.).
18. David K.A., Milowsky M.I., Ritchey J., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998-2003: A report from the national cancer data base. J Urol 2007, 178:451-454.
19. Miles B.J., Fairey A.S., Eliasziw M., et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010, 4:262-266.
20. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006, 24:3967-3972. International Bladder Cancer Nomogram Consortium.